InMed Pharmaceuticals (INM) Net Cash Flow (2019 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Net Cash Flow of -$1.5 million for Q1 2026, down 216.11% year-over-year from $1.3 million in Q1 2025, and up 38.41% quarter-over-quarter from -$2.4 million in Q4 2025.
InMed Pharmaceuticals (INM) Net Cash Flow (2019 - 2026) Analysis & Trends
InMed Pharmaceuticals' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$1.5 million for Q1 2026.
- In Q1 2026, Net Cash Flow fell 216.11% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at $811547.0 (up 127.79% YoY), while the FY2025 annual figure was $4.5 million, up 292.42% from the prior year.
- Net Cash Flow for Q1 2026 stood at -$1.5 million, up from -$2.4 million in the prior quarter.
- The five-year high for Net Cash Flow was $6.4 million in Q2 2025, with the low at -$5.4 million in Q1 2022.
- The 5-year median for Net Cash Flow is -$1.5 million (2026), against an average of -$584314.2.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow slumped 849.58% in 2022, then surged 721.59% in 2025.
- InMed Pharmaceuticals' Net Cash Flow stood at $2.6 million in 2022, then sank by 171.02% to -$1.8 million in 2023, then declined by 17.07% to -$2.2 million in 2024, then declined by 9.83% to -$2.4 million in 2025, then jumped by 38.41% to -$1.5 million in 2026.
- Business Quant data shows INM's Net Cash Flow at -$1.5 million in Q1 2026, -$2.4 million in Q4 2025, and -$1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | -81.00 Mn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | -458.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | -881.03 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 523.50 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -912.40 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 64.40 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 93.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.56 Mn | 1.32 Mn | - | -1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.46 Mn |
| Mar 31, 2026 | -1.46 Mn |
| Dec 31, 2025 | -2.38 Mn |
| Dec 31, 2025 | -2.38 Mn |
| Sep 30, 2025 | -1.74 Mn |
| Sep 30, 2025 | -1.74 Mn |
| Jun 30, 2025 | 6.40 Mn |
| Jun 30, 2025 | 6.40 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Dec 31, 2024 | -2.16 Mn |
| Dec 31, 2024 | -2.16 Mn |
| Sep 30, 2024 | -988,571.00 |
| Sep 30, 2024 | -988,571.00 |
| Jun 30, 2024 | -1.03 Mn |
| Jun 30, 2024 | -1.03 Mn |
| Mar 31, 2024 | -1.93 Mn |
| Mar 31, 2024 | -1.93 Mn |
| Dec 31, 2023 | -1.85 Mn |
| Dec 31, 2023 | -1.85 Mn |